Lightbridge Corporation (Nasdaq: LTBR) — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparable figures are for 2022. The filing was dated March 4, 2024. Lightbridge is a pre-revenue company developing metallic nuclear fuel and has not commercialized its technology.
Financial performance and position
- Revenue: $0 in both 2023 and 2022. Gross margin is not applicable.
- Operating expenses: $9.07 million, up 11% from $8.16 million. General and administrative expense decreased to $7.15 million from $7.49 million; research and development (R&D) expense increased to $1.92 million from $0.67 million.
- Operating loss: $9.04 million, compared with $7.79 million in 2022. Interest income of $1.13 million, up from $0.29 million, partly offset the operating loss. Net loss was $7.91 million versus $7.50 million; loss per share was $0.65 versus $0.69.
- Cash flow: Operating cash used was $6.48 million, compared with $6.76 million in 2022. Financing provided $6.18 million, primarily from common-stock sales; cash declined by $0.30 million to $28.60 million.
- Liquidity and debt: Current assets were $28.81 million and current liabilities were $0.49 million at year-end; working capital was approximately $28.2 million. The company reported no debt or credit lines. Total stockholders’ equity was $28.91 million.
- Capital raised and dilution: ATM sales generated $6.4 million net in 2023 from approximately 1.49 million shares, versus $11.0 million from approximately 1.86 million shares in 2022. Shares outstanding increased to 13.70 million from 11.90 million.
Material changes and business developments
- R&D expense rose as work on fuel development with Idaho National Laboratory (INL) expanded. G&A expense fell, partly because more employee costs were allocated to R&D. Higher Treasury-bill and savings-account rates increased interest income.
- The company signed a Centrus Energy agreement for a pilot fuel fabrication facility front-end engineering and design study, expected to cost approximately $0.5 million and finish in 2024. It also began a CANDU-reactor engineering study expected to cost approximately $0.2 million and finish in 2024.
- During 2023, Lightbridge worked with INL on quality planning and demonstrated casting laboratory-scale uranium-zirconium ingots using depleted uranium. Enriched-uranium material coupons for irradiation testing at INL’s Advanced Test Reactor (ATR) are anticipated to be inserted in 2025, subject to the development plan and facility availability.
- The company reported 11 U.S. patents and more than 146 foreign patents at year-end, with 12 patent applications pending worldwide. U.S. patents begin to expire in 2027.
Outlook, risks and contingencies
- Management expects existing cash resources to cover operating needs for the next 12 months and estimates approximately $13.8 million of total expenditures over that period. It anticipates R&D investment of approximately $6–8 million over the next 12–15 months. These estimates are subject to uncertainty.
- Long-term development is estimated to require an average of approximately $10 million annually in outside R&D spending over 10–15 years. The company says commercialization could require several hundred million dollars; it currently estimates initial commercial reload orders could be 15–20 years away, with lead test rods or assemblies targeted for the 2030s.
- Lightbridge’s development schedule depends on additional funding or in-kind support, government and strategic-partner participation, access to suitable irradiation test capacity, HALEU supply and infrastructure, successful fabrication and testing, regulatory approvals, and utility and fuel-vendor partnerships. The company warns that delays, higher costs, or failure to secure funding could materially impede development.
- Management states that ATM equity sales may continue to fund operations; further equity financing could dilute shareholders. The company was subject to “baby shelf” limits on certain public offerings and its existing shelf registration was due to expire in April 2024.
- Technology and market risks include unproven commercial-reactor performance, licensing and manufacturing uncertainty, potentially high production costs, competition from accident-tolerant fuels and other energy sources, and the possibility that expected fuel economics or safety benefits are not realized.
- At December 31, 2023, management identified a material weakness in internal control over financial reporting related to logical access controls and segregation of duties in certain IT environments. Remediation had begun but was not yet considered complete. A previously reported accounts-payable control weakness was considered remediated. The auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal control effectiveness.
- Approximately $3.6 million of R&D commitments were outstanding at year-end, principally $2.9 million to INL, $0.2 million for the CANDU study, and $0.5 million for the Centrus study. The filing reported no current pending legal proceedings known to the company.
Key facts for investors to verify
- Progress, funding, cost estimates, and timing for INL irradiation work, ATR loop availability, the Centrus facility study, and CANDU feasibility work.
- Cash burn, projected spending, remaining ATM capacity, shelf-registration status, and the company’s ability to obtain government or partner support without excessive dilution.
- Remediation and testing of the IT access and segregation-of-duties controls weakness.
- Whether HALEU supply, fuel fabrication, regulatory licensing, and commercial utility partnerships can be secured on viable terms.
- Whether technical testing and updated economic analyses support the projected performance, safety, and cost benefits of Lightbridge Fuel.